Combining clonazepam and MDMA is generally advised against. Clonazepam (brand name: Rivotril) is a powerful anti-anxiety drug that suppresses the central nervous system. MDMA, on the other hand, has a stimulating effect and enhances emotional processing. If you have Clonazepam in your system during a MDMA session, the effects of MDMA can become flattened or unpredictable. You may then miss the therapeutic window that makes MDMA therapy so effective.

Additionally, this combination can:

1. The chance of side effects or confusion enlarge.

2. Emotional flattening cause, which can reduce the depth of a therapeutic session.

3. In extreme cases, lead to paradoxical reactions, such as heightened anxiety, precisely due to the interaction between inhibition and stimulation.

With us the use of benzodiazepines such as clonazepam is considered a contraindication considered for MDMA sessions. You are then advised to taper off first (in consultation with your doctor), so that the substance is no longer active during the session. However, this must always carefully and under medical supervision happen, because suddenly stopping Clonazepam can be dangerous.

For a safe MDMA session (or session with a MDMA analogue), it is recommended to at least 5 times the half-life of Clonazepam to wait after the last intake — in other words: about 6 to 10 days after the last dose of Clonazepam, depending on your personal metabolism.

If you are considering an MDMA session and you use Clonazepam, it is essential to honestly disclose this in the intake. Then the team can assess whether you can have a session at a safe time, or whether another form of psychedelic therapy (such as a psilocybin session) fits better.

Clonazepam Clonazepam is a potent benzodiazepine that acts as an allosteric modulator of GABA-A receptors. It increases the frequency with which GABA opens chloride channels, resulting in neuronal hyperpolarization and inhibition. This explains the sedative, anxiolytic, anticonvulsive, and muscle relaxant effects produced by clonazepam. Clonazepam is rapidly absorbed after oral administration and reaches peak concentrations after a few hours. It has a long half-life (approximately 30–40 hours) and is primarily broken down in the liver via CYP3A enzymes. The unchanged substance and one major metabolite (7-amino-clonazepam) are eliminated via the kidneys. Due to the long half-life, the effect can persist for a long time, but this also means that accumulation can occur with successive doses.

MDMA (3,4-methylenedioxymethamphetamine) MDMA is a ring-substituted amphetamine primarily known as an entactogen or empathogen. Pharmacodynamically, MDMA primarily stimulates the release of serotonin (5-HT), but also of norepinephrine and dopamine. MDMA enters the neuron via monoamine transporter proteins (e.g., SERT) and subsequently blocks VMAT2, allowing many neurotransmitters to flow into the synaptic cleft. As a result, extracellular 5-HT concentration rises dramatically, leading to greatly increased euphoria, empathic bonding, and social openness. MDMA also acts as a weak agonist on 5-HT1A and 5-HT2A receptors and indirectly causes an increase in oxytocin (the “cuddle hormone”) via serotonergic mechanisms. Clinical studies show that MDMA increases heart rate and blood pressure in a dose-dependent manner and subjectively induces feelings of euphoria and sociability. At the same time, MDMA often reduces the recognition of negative emotions (such as fear or anger) in others, which contributes to a sense of connectedness.

In the liver, MDMA is largely metabolized by CYP2D6 (autoinhibitory effect) and, to a lesser extent, by CYP3A4 and COMT, resulting in complex pharmacokinetics. The half-life of MDMA is in the order of 6–10 hours (the psychoactive effects can last for several hours, typically 3–5 hours). Due to these metabolic characteristics, repeated administration within a short period can lead to accumulation and increased risk.

Effects of simultaneous use

In practice, the stimulating effects of MDMA and the calming effects of clonazepam are usually considered opposite. Clonazepam increases inhibition via GABA, which generally slows down the central nervous system, whereas MDMA primarily induces excitement and emotional openness through serotonin and oxytocin. According to DrugBank does the combination of MDMA with benzodiazepines lead to an increased risk of CNS depression“The risk or severity of CNS depression can be increased when MDMA is combined with 1,2-Benzodiazepine.” In other words, the sedative effect of clonazepam can partially “suppress” or mitigate the stimulation caused by MDMA. This can temper the subjective intensity of the MDMA experience. Some experts note that benzodiazepines reduce the anxiogenic (anxious) component of an MDMA trip, while the euphoric and empathogenic effects do not disappear as immediately. In any case, no direct antagonism of the serotonergic effects is known; clonazepam does not target the same receptors as MDMA. However, clinical guidelines indicate that in worst-case scenarios, benzodiazepines are the drug of choice to control acute panic or anxiety during a psychedelic session.

In published studies with MDMA, patients typically did not use concomitant benzodiazepines (MDMA therapy series often exclude sedatives), so there are no controlled studies that quantify the combination. However, a pharmacokinetic analysis (Cohen et al., 2021) based on poisoning reports indicates that in polydrug situations involving MDMA intake, concomitant use of benzodiazepines was associated with a significantly increased risk of death (odds ratio 13.5) compared to MDMA alone. This suggests that the combination in particular may cause complications, although it is unclear whether this was due to the severity of the scenario or a direct physiological effect. In short, clonazepam will not entirely “neutralize” MDMA’s effects, but will (partially) dampen them through sedation and anxiety reduction. The precise effect on empathy or emotional openness has not been investigated, but in practice, overly sedative medication can reduce therapeutic breakthrough. On the other hand, it may actually facilitate adherence and anxiety management.

Risks and safety profile

The combined use of MDMA and clonazepam carries several potential risks. MDMA is a sympathomimetic agent: it increases heart rate and blood pressure. Clonazepam (a benzodiazepine), on the other hand, can cause hypotension and respiratory depression at high doses or in combination with other sedatives. The opposing effects can have unpredictable outcomes. For instance, clonazepam can mask hyperstimulation, potentially leading users to take more MDMA or other substances to achieve the desired effect. One scenario is that the stimulating and sedative effects cause a “tug-of-war” in the central nervous system. Practically, this increases the risk of overdose: the sedative effects of clonazepam can suppress breathing and consciousness without the user fully realizing it, while MDMA puts a strain on the cardiovascular system.

In a clinical setting, however, sedation with benzodiazepines is actually recommended for MDMA intoxications to combat agitation, muscle spasms, and hypertension. Medscape recommends administering benzodiazepines for sedation and antispasmodic effects; strong stimulation (such as from amphetamines) can be kept in check by sedation, which can lower blood pressure. This demonstrates that clonazepam can act as an acute protective agent against the cardiovascular stress of MDMA. On the other hand, there is no specific contraindication for combining them, but caution is advised: both substances have dependency potential, and co-use can exacerbate neuropsychological side effects (such as confusion or memory impairment). Neurologically, clonazepam reduces the risk of seizures, which can be beneficial with high doses of MDMA accompanied by seizures. However, one must be careful as clonazepam itself causes sedation and drowsiness, which can be dangerous in cases of fall risk or while driving.

Cardiovascularly, combined effects can lead to both hypertension (due to MDMA) and hypotension (due to clonazepam). This can trigger arrhythmias or fainting, particularly in vulnerable individuals. At high doses of clonazepam, there is a general risk of respiratory depression (especially in combinations with alcohol/opioids), but this is less applicable with MDMA alone because MDMA has a stimulating effect. Finally, combination use can be misleading for diagnosis: symptoms such as reduced alertness or extreme dizziness can stem from both MDMA and clonazepam.

In summary: although clonazepam can offer an anxiolytic and anticonvulsive benefit during an MDMA session, the combination requires careful dosing. The stimulating cardiovascular burden of MDMA remains; benzodiazepines can partially mitigate this but primarily carry the risk of excessive sedation. An analysis of MDMA-related deaths showed that benzodiazepines—more often than other categories such as opioids or alcohol—were associated with increased mortality. This points to an unfavorable safety profile if the combination is misused. Furthermore, it is important to emphasize that benzodiazepines should preferably only be used when the effects of MDMA are too strong and medical intervention is required (in the absence of other means), and not as a precautionary measure.

Clonazepam before or after an MDMA session

In a therapeutic context, the use of clonazepam prior to an MDMA session is rarely standard practice. Generally, the goal is for the patient to be fully receptive to the entactogenic effects. An excessively high dose of clonazepam beforehand can actually dampen the intensity and impair the therapy. No protocols are found in the literature prescribing clonazepam as standard premedication; however, it is recommended to instruct patients to relax beforehand and, if necessary, to apply light sedation with breathing exercises.

Clonazepam can, however. after a session may be initiated. Both administrative MDMA-AT protocols and clinical package inserts provide for the use of benzodiazepines to manage severe adverse effects. For instance, the MAPS MDMA-PTSD protocols explicitly state that patients may receive benzodiazepines (or zolpidem) after an experimental MDMA session to combat acute anxiety, panic, or insomnia. During a “stabilization period” of several hours, therapists may decide to administer clonazepam if there is persistent, severe emotional distress. Such emergency medication is only used if the intensity of the experience becomes unbearable.

As a “trip-stopper” (the abrupt termination of the experience), clonazepam is rarely mentioned; the Johnson et al.Guidelines for psychedelics specifically emphasize that diazepam or lorazepam are primarily intended to relieve anxiety, not to completely cancel out the drug effects. It is extensively described that 10 mg of oral diazepam is effective in reducing acute anxiety during a “bad trip”. This applies to MDMA: in extreme cases, a comparable dose of clonazepam (approximately 0.5–2 mg) can have a calming effect, although data specifically for MDMA are lacking.

Anecdotally, users report that clonazepam is sometimes used before MDMA to reduce nervous excitement, but one should then expect a more muted “high.” Some consider clonazepam as a safety net after the session to eliminate overload (for example, to fall asleep quickly or to stop an acute panic attack). In practice, this is sometimes done, but therapists prefer a gradual integration of the experience; after all, excessive sedation afterwards can overshadow the therapeutic impressions.

Clinical insights and literature

There are few published cases or trial scores that specifically combine clonazepam and MDMA. However, review articles emphasize the need for research: Johnson et al. advocates for having benzodiazepines on standby for emergencies regarding psychedelics. A recent review of MDMA research indicates that practitioners in trials use benzodiazepines for overwhelming anxiety. In contrast, a review (Cohen et al., 2021) in which it was reported that co-use in MDMA-related incidents was associated with more fatal outcomes, and that there is effectively no randomized study on the MDMA+benzo combination.

We know from experimental studies that MDMA itself promotes empathy and prosociality. For instance, in a placebo-controlled study, MDMA was found to increase emotions such as compassion and social connectedness. This is relevant for therapeutic purposes. Clonazepam, on the other hand, generally reduces feelings of anxiety but does not lead to empathy and can cause cognitive inhibition. The combined effect is presumably that the patient makes contact (MDMA) but experiences less intense physical arousal (clonazepam).

In shortThe combination of clonazepam and MDMA in therapy can potentially be useful for mitigating (extreme) anxiety, but it also carries the risk of under-response or side effects. The literature does not provide unambiguous warnings against the occasional administration of clonazepam in MDMA therapy, provided it is carefully dosed. However, experts point out that benzodiazepines should be considered in this context. carefully must be applied and not routinely, given the risk that they stifle the necessary therapeutic breakthrough. In practice, practitioners should assess each case individually and always apply observation and follow-up if side effects occur. For the time being, it seems better to minimize the influence of benzodiazepines such as clonazepam before and during therapeutic sessions with MDMA; tapering off under supervision beforehand is advised.

No, it is better not to use them at the same time!